CEL-SCI Corp
AMEX:CVM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
CEL-SCI Corp
AMEX:CVM
|
US |
|
Northway Financial Inc
OTC:NWYF
|
US |
|
T
|
Taekyung Chemical Co Ltd
KRX:006890
|
KR |
|
A
|
ASN Broker PCL
SET:ASN
|
TH |
|
Atlantic Navigation Holdings (Singapore) Ltd
SGX:5UL
|
SG |
|
Winnebago Industries Inc
NYSE:WGO
|
US |
|
Bexcellent Group Holdings Ltd
HKEX:1775
|
HK |
|
Gene Biotherapeutics Inc
OTC:CRXM
|
US |
|
T
|
Tonghua Dongbao Pharmaceutical Co Ltd
SSE:600867
|
CN |
|
Foshan Golden Milky Way Intelligent Equipment Co Ltd
SZSE:300619
|
CN |
|
MMTEC Inc
NASDAQ:MTC
|
CN |
|
technotrans SE
XETRA:TTR1
|
DE |
|
C
|
Changzhou Evergreen Technology Co Ltd
SZSE:001324
|
CN |
|
S
|
Seven West Media Ltd
SWB:WA7
|
AU |
|
M
|
Mobirix Corp
KOSDAQ:348030
|
KR |
CEL-SCI Corp
CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The firm is focused on activating the immune system to fight cancer and infectious diseases. The firm is engaged in research and developing of treatments for cancer and other diseases by using the immune system. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal phase III clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The firm is using its Ligand Epitope Antigen Presentation System (LEAPS) technology to develop various new drug candidates, CEL-4000 and CEL-2000, as potential rheumatoid arthritis therapeutic treatments. Its product candidates using its LEAPS technology are CEL-2000, CEL-4000 and DerG-PG275(Cit). The Company’s Multikine is an immunotherapy product candidate comprised of a patented defined mixture of 14 human natural cytokines.
CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The firm is focused on activating the immune system to fight cancer and infectious diseases. The firm is engaged in research and developing of treatments for cancer and other diseases by using the immune system. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal phase III clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The firm is using its Ligand Epitope Antigen Presentation System (LEAPS) technology to develop various new drug candidates, CEL-4000 and CEL-2000, as potential rheumatoid arthritis therapeutic treatments. Its product candidates using its LEAPS technology are CEL-2000, CEL-4000 and DerG-PG275(Cit). The Company’s Multikine is an immunotherapy product candidate comprised of a patented defined mixture of 14 human natural cytokines.
